NSCLC's prescriber base is roughly 13,000 US oncologists, concentrated enough that account depth, not reach, decides field strategy.

NSCLC is prescribed almost entirely by medical and hematology-oncologists, a concentrated specialist base of roughly 13,000 practicing US oncologists clustered in academic cancer centers and large community-oncology networks such as US Oncology and OneOncology. Volume concentrates further within that base: a minority of high-volume thoracic-oncology accounts drives the majority of eligible patients, so the addressable target list is small and identifiable, and the commercial question is account penetration and depth, not breadth of reach.

Two structural facts set the field model. First, channel: infused immuno-oncology and chemotherapy are buy-and-bill under Medicare Part B, while oral targeted agents for EGFR, ALK, ROS1, and KRAS-G12C route through Part D, so field roles must cover both the practice-economics conversation and the pharmacy-access one. Second, targeting is biomarker-gated: EGFR, ALK, ROS1, and PD-L1 testing determines eligibility, so the field and MSL effort centers on driving comprehensive biomarker testing and positioning within the tested subpopulation. The result is a small, account-based key-account-manager plus medical-science-liaison model with long, relationship-led cycles, structurally different from a primary-care field force.

Reach doesn't win in NSCLC; depth into a small account list does.

Five questions this report answers:

Q1 - How small is the real NSCLC target list once you concentrate on high-volume thoracic accounts?

Q2 - How do field roles split across the buy-and-bill Part B and oral Part D channels?

Q3 - How does biomarker-gated eligibility change NSCLC targeting and the MSL-commercial split?

Q4 - How many US oncologists make up the entire NSCLC prescriber base?

Q5 - Which large community-oncology networks concentrate the highest-volume thoracic-oncology accounts in the US?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#NSCLC #FieldForceStrategy #OncologyCommercial #SFE #MedicarePartB #US

Live report page:  https://axlrx.ai/nsclc/field-force-strategy/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                                     hello@axlrx.ai

Web-                                     https://axlrx.ai/